On 24 January 2013, orphan designation (EU/3/12/1087) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for recombinant modified human growth hormone for the treatment of growth-hormone deficiency.
The sponsorship was transferred to Richardson Associates Regulatory Affairs Ltd, Ireland, in December 2018.
The sponsorship was transferred to Pfizer Europe MA EEIG, Belgium, in April 2020.
Recombinant modified human growth hormone
|Disease / condition||
Treatment of growth hormone deficiency
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.